SCHEMBL5296286

SCHEMBL5296286

CCCCC(C)C(N)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 2/20 0.50
SLC1A1 P43005 2/20 0.50
SLC1A3 P43003 1/20 0.50
CA2 P00918 2/20 0.48
MAPK1 P28482 1/20 0.48
SLC7A5 Q01650 1/20 0.46
GRIK1 P39086 2/20 0.44
GRIK2 Q13002 2/20 0.44
SLC15A1 P46059 1/20 0.44
ACE2 Q9BYF1 1/20 0.42
DPP4 P27487 1/20 0.42
DPP8 Q6V1X1 1/20 0.42
DPP9 Q86TI2 1/20 0.42
DPP7 Q9UHL4 1/20 0.42
GPR84 Q9NQS5 3/20 0.42
CA1 P00915 1/20 0.42
FFAR1 O14842 1/20 0.42
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8666519 1.00 SLC1A2 (0.50) SLC1A2SLC1A1SLC1A3CA2MAPK1
SCHEMBL31370048 1.00 SLC1A2 (0.50) SLC1A2SLC1A1SLC1A3CA2MAPK1
Hydrochloric Acid SCHEMBL7058777 0.98 SLC1A2 (0.48) SLC1A2SLC1A1SLC1A3CA2MAPK1
SCHEMBL7060883 0.98 SLC1A2 (0.48) SLC1A2SLC1A1SLC1A3CA2MAPK1
SCHEMBL4544292 0.94 GRIK1 (0.52) SLC1A2SLC1A1SLC1A3SLC7A5GRIK1
SCHEMBL4544294 0.94 GRIK1 (0.52) SLC1A2SLC1A1SLC1A3SLC7A5GRIK1
SCHEMBL7079206 0.92 GPR84 (0.53) SLC1A2SLC1A1GRIK1GRIK2ACE2
SCHEMBL6139186 0.92 GPR84 (0.53) SLC1A2SLC1A1GRIK1GRIK2ACE2
SCHEMBL5296193 0.92 GPR84 (0.53) SLC1A2SLC1A1GRIK1GRIK2ACE2
Hydrochloric Acid SCHEMBL7053878 0.92 GRIK1 (0.50) SLC1A2SLC1A1SLC1A3SLC7A5GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US claimed
US-20030229145-A1 Pain treatment methods and compositions GRUENENTHAL GMBH (DE) 2003-12-11 US claimed
EP-1326826-A1 USE OF AMINO ACIDS FOR TREATING PAIN Grünenthal GmbH (DE) 2003-07-16 EP claimed
WO-2002030871-A1 USE OF AMINO ACIDS FOR TREATING PAIN Grünenthal GmbH (DE) 2002-04-18 WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US claimed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
CN-113214130-A Herbicidal use of chiral pyrrolidone derivatives 南京农业大学 2021-08-06 CN disclosed
WO-2007002469-A2 THERAPEUTIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS BHATNAGAR RAJENDRA S (US) 2007-01-04 WO disclosed
WO-2007002594-A1 COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS BHATNAGAR RAJENDRA S (US) 2007-01-04 WO disclosed
US-20060293228-A1 Therapeutic compositions and methods using transforming growth factor-beta mimics BHATNAGAR RAJENDRA S 2006-12-28 US disclosed
US-20060293227-A1 Cosmetic compositions and methods using transforming growth factor-beta mimics BHATNAGAR RAJENDRA S 2006-12-28 US disclosed
US-6939854-B2 Peptide inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-09-06 US disclosed
WO-2002030871-A1 USE OF AMINO ACIDS FOR TREATING PAIN Grünenthal GmbH (DE) 2002-04-18 WO disclosed
EP-1196436-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-04-17 EP disclosed
WO-2001064678-A2 INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-09-07 WO disclosed
WO-2001040262-A1 ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-06-07 WO disclosed
WO-2001002424-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE DU PONT PHARMACEUTICALS COMPANY (US) 2001-01-11 WO disclosed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US disclosed
EP-0787010-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-06 EP disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229145-A1 Pain treatment methods and compositions AADAT, BCAT2, BCAT1 SLC1A2 10/4885SLC1A1 16/4885SLC1A3 34/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 SLC1A2 369/4885SLC1A1 305/4885SLC1A3 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.